Helicobacter pylori infection in hepatic encephalopathy: Relationship to plasma endotoxins and blood ammonia

Hepatology Research

Volumn 37, Issue 12, 2007, Pages 1026-1033

  Abdel Hady, Hassan ^a   Zaki, Ali ^a   Badra, Gamal ^a   Lotfy, Mahmoud ^b   Selmi, Carlo ^c,d   Giorgini, Alessia ^c   El Sayed, Mohamed ^a   Badr, Reda ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ammonia; Endotoxins; Helicobacter pylori; Hepatic encephalopathy; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENDOTOXIN; METRONIDAZOLE; OMEPRAZOLE; PROTEIN; PROTHROMBIN;

ADULT; AGE; AMMONIA BLOOD LEVEL; ARTICLE; ASCITES; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE SEVERITY; ELECTROENCEPHALOGRAPHY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTHROMBIN TIME; PSYCHOMETRY; STOMACH BIOPSY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 35648999470     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00146.x     Document Type: Article

References (42)

1. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004; 19: 253-67.
2. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 473-9.
3. Zeneroli ML, Avallone R, Corsi L, Venturini I, Baraldi C, Baraldi M. Management of hepatic encephalopathy: Role of rifaximin. Chemotherapy 2005; 51 (Suppl 1): 90-5.
4. LeVeen HH, LeVeen EG, LeVeen RF. Awakenings to the pathogenicity of urease and the requirement for continuous long-term therapy. Biomed Pharmacother 1994; 48: 157-66.
5. Farinati F, De Bona M, Floreani A, Foschia F, Rugge M. Helicobacter pylori and the liver: Any relationship? Ital J Gastroenterol Hepatol 1998; 30: 124-8.
6. Zullo A, Hassan C, Morini S. Helicobacter pylori infection in patients with liver cirrhosis: Facts and fictions. Dig Liver Dis 2003; 35: 197-205.
7. Boermeester MA, Straatsburg IH, Houdijk AP et al. Endotoxin and interleukin-1 related hepatic inflammatory response promotes liver failure after partial hepatectomy. Hepatology 1995; 22: 1499-506.
8. Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: The model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005; 22: 1079-89.
9. Sood GK, Sarin SK, Mahaptra J, Broor SL. Comparative efficacy of psychometric tests in detection of subclinical hepatic encephalopathy in nonalcoholic cirrhotics: Search for a rational approach. Am J Gastroenterol 1989; 84: 156-9.
10. Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World congresses of gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
11. Dhiman RK, Saraswat VA, Verma M, Naik SR. Figure connection: A universal test for assessment of mental state. J Gastroenterol Hepatol 1995; 10: 14-23.
12. Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 541-50.
13. Serhat B, Galip E, Canan B, Ömer Ö, Salih AU, Yücel B. Number connection test results of normal volunteers. Turk J Gastroenterol 2000; 11: 49-53.
14. Zullo A, Rinaldi V, Meddi P et al. Helicobacter pylori infection in dyspeptic cirrhotic patients. Hepatogastroenterology 1999; 46: 395-400.
15. Rudman D, DiFulco TJ, Galambos JT, Smith RB 3rd, Salam AA, Warren WD. Maximal rates of excretion and synthesis of urea in normal and cirrhotic subjects. J Clin Invest 1973; 52: 2241-9.
16. Dasani BM, Sigal SH, Lieber CS. Analysis of risk factors for chronic hepatic encephalopathy: The role of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 726-31.
17. Zullo A, Rinaldi V, Meddi P, Hassan C, Winn S, Attili AF. Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Am J Gastroenterol 1999; 94: 2214-18.
18. Rossle M, Haag K, Ochs A et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165-71.
19. Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO Jr, McClain CJ. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980; 140: 519-21.
20. Weber FL Jr, Banwell JG, Fresard KM, Cummings JH. Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin. J Lab Clin Med 1987; 110: 259-63.
21. Ferenci P. Pathophysiology of hepatic encephalopathy. Hepatogastroenterology 1991; 38: 371-6.
22. Butterworth RF. Pathogenesis and treatment of portal-systemic encephalopathy: An update. Dig Dis Sci 1992; 37: 321-7.
23. Weissenborn K. Recent developments in the pathophysiology and treatment of hepatic encephalopathy. Baillieres Clin Gastroenterol 1992; 6: 609-30.
24. Xu C, Jiang X. Relationship between Helicobacter pylori infection and cirrhosis of liver. Hunan Yi Ke Da Xue Xue Bao 1998; 23: 382-4. (In Chinese.)
25. Misra SP, Dwivedi M, Misra V et al. Endoscopic and histologic appearance of the gastric mucosa in patients with portal hypertension. Gastrointest Endosc 1990; 36: 575-9.
26. Demirturk L, Yazgan Y, Zci O et al. The effect of Helicobacter pylori eradication on gastric juice and blood ammonia concentrations and on visual evoked potentials in cirrhotics. Helicobacter 2001; 6: 325-30.
27. Zullo A, Hassan C, Morini S. Hepatic encephalopathy and Helicobacter pylori: A critical reappraisal. J Clin Gastroenterol 2003; 37: 164-8.
28. Lin RS, Lee FY, Lee SD et al. Endotoxemia in patients with chronic liver diseases: Relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22: 165-72.
29. Ruiter DJ, van der Meulen J, Brouwer A et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest 1981; 45: 38-45.
30. Loda M, Clowes GH Jr, Nespoli A, Bigatello L, Birkett DH, Menzoian JO. Encephalopathy, oxygen consumption, visceral amino acid clearance, and mortality in cirrhotic surgical patients. Am J Surg 1984; 147: 542-50.
31. Bigatello LM, Broitman SA, Fattori L et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol 1987; 82: 11-15.
32. de Vries HE, Blom-Roosemalen MC, van Oosten M et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996; 64: 37-43.
33. Odeh M. Endotoxin and tumor necrosis factor-alpha in the pathogenesis of hepatic encephalopathy. J Clin Gastroenterol 1994; 19: 146-53.
34. Bliss CM Jr, Golenbock DT, Keates S, Linevsky JK, Kelly CP. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. infect Immun 1998; 66: 5357-63.
35. Giannini E, Fasoli A, Borro P et al. Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1967-73.
36. Whittle BJ, Morschl E, Pozsar J, Moran AP, Laszlo F. Helicobacter pylori lipopolysaccharide provokes iNOS-mediated acute systemic microvascular inflammatory responses in rat cardiac, hepatic, renal and pulmonary tissues. J Physiol Paris 2001; 95: 257-9.
37. Megraud F. Toxic factors of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6 (1 Suppl): 5S-10S.
38. Dytoc M, Gold B, Louie M et al. Comparison of Helicobacter pylori and attaching-effacing Escherichia coli adhesion to eukaryotic cells. Infect Immun 1993; 61: 448-56.
39. Rietschel ET, Brade H. Bacterial endotoxins. Sci Am 1992; 267: 54-61.
40. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Ann Rev Med 1987; 38: 417-32.
41. Tsang KW, Lam SK. Extragastroduodenal conditions associated with Helicobacter pylori infection. Hong Kong Med J 1999; 5: 169-74.
42. Gonciarz M, Wloch M, Gonciarz Z. Helicobacter pylori in liver diseases. J Physiol Pharmacol 2006; 57 (Suppl 3): 155-61.